Ítem
Acceso Abierto

Efficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenac

Mostrar el registro sencillo de la publicación
dc.creatorWeckx L.L.M.spa
dc.creatorRuiz J.E.spa
dc.creatorDuperly J.spa
dc.creatorMartínez Mendizabal G.A.spa
dc.creatorRausis M.B.G.spa
dc.creatorPiltcher S.L.spa
dc.creatorSaffer M.spa
dc.creatorMatsuyama C.spa
dc.creatorLevy S.spa
dc.creatorFort J.G.spa
dc.date.accessioned2020-05-25T23:56:17Z
dc.date.available2020-05-25T23:56:17Z
dc.date.created2002spa
dc.description.abstractThis study compared the efficacy and safety of the cyclooxygenase-2 specific inhibitor celecoxib with the conventional non-steroidal anti-inflammatory drug diclofenac in the symptomatic treatment of viral pharyngitis. Adult patients from 27 study centers in Latin America were treated with oral doses of celecoxib 200 mg once daily or 200 mg twice daily, or diclofenac 75 mg twice daily for 5 days in a double-blind, randomized study. The primary efficacy assessment was 'Throat Pain on Swallowing' on day 3. In addition, secondary quality-of-life assessments were performed on days 3 and 5. All adverse events and treatment-emergent signs and symptoms were recorded. Data from 313 patients were evaluable for efficacy (105 celecoxib 200 mg once daily, 107 celecoxib 200 mg twice daily, 101 diclofenac 75 mg twice daily). The upper 95% confidence limits for the visual analog scale of 'Throat Pain on Swallowing' on day 3 for celecoxib 200 mg once daily relative to diclofenac 75 mg twice daily, and celecoxib 200 mg twice daily relative to diclofenac 75 mg twice daily were 9.26 and 7.83, respectively. All secondary efficacy and quality-of-life measures were clinically similar for the three treatment groups, and no statistically significant differences were detected. The incidences of treatment-emergent adverse events and withdrawals due to adverse events were similar for all groups, but numerically higher among patients taking diclofenac than celecoxib. More patients in the diclofenac group reported gastrointestinal complaints (7.3%) compared with those in the celecoxib groups (4.3% in the celecoxib 200 mg once-daily group and 3.4% in the celecoxib 200 mg twice-daily group). In conclusion, 5 days of treatment with celecoxib 200 mg once daily is as effective as diclofenac 75 mg twice daily in the symptomatic treatment of viral pharyngitis. Celecoxib 200 mg once daily is also as effective as celecoxib 200 mg twice daily in this condition.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1177/147323000203000212
dc.identifier.issn3000605
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22385
dc.language.isoengspa
dc.relation.citationEndPage194
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage185
dc.relation.citationTitleJournal of International Medical Research
dc.relation.citationVolumeVol. 30
dc.relation.ispartofJournal of International Medical Research, ISSN:3000605, Vol.30, No.2 (2002); pp. 185-194spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0036012820&doi=10.1177%2f147323000203000212&partnerID=40&md5=665f2d2194aadafc6c490eb871698745spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordCelecoxibspa
dc.subject.keywordnon-steroidaleng
dc.subject.keywordDiclofenacspa
dc.subject.keywordNonsteroid antiinflammatory agentspa
dc.subject.keywordCelecoxibspa
dc.subject.keywordDiclofenacspa
dc.subject.keywordNonsteroid antiinflammatory agentspa
dc.subject.keywordProstaglandin synthase inhibitorspa
dc.subject.keywordPyrazole derivativespa
dc.subject.keywordSulfonamidespa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordClinical trialspa
dc.subject.keywordControlled clinical trialspa
dc.subject.keywordControlled studyspa
dc.subject.keywordDouble blind procedurespa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordDrug safetyspa
dc.subject.keywordDrug withdrawalspa
dc.subject.keywordDysphoniaspa
dc.subject.keywordFemalespa
dc.subject.keywordFeverspa
dc.subject.keywordGastrointestinal diseasespa
dc.subject.keywordHeadachespa
dc.subject.keywordHumanspa
dc.subject.keywordIncidencespa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordNose congestionspa
dc.subject.keywordPatient satisfactionspa
dc.subject.keywordPharyngitisspa
dc.subject.keywordQuality of lifespa
dc.subject.keywordRandomized controlled trialspa
dc.subject.keywordSinusitisspa
dc.subject.keywordSore throatspa
dc.subject.keywordSouth and central americaspa
dc.subject.keywordSwallowingspa
dc.subject.keywordSymptomspa
dc.subject.keywordVertigospa
dc.subject.keywordVisual analog scalespa
dc.subject.keywordAdolescentspa
dc.subject.keywordAgedspa
dc.subject.keywordCohort analysisspa
dc.subject.keywordComparative studyspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPain assessmentspa
dc.subject.keywordPathophysiologyspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVirus infectionspa
dc.subject.keywordAdolescentspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAnti-inflammatory agentseng
dc.subject.keywordCohort studiesspa
dc.subject.keywordCyclooxygenase inhibitorsspa
dc.subject.keywordDiclofenacspa
dc.subject.keywordDouble-blind methodspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordPain measurementspa
dc.subject.keywordPharyngitisspa
dc.subject.keywordPyrazolesspa
dc.subject.keywordQuality of lifespa
dc.subject.keywordSulfonamidesspa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVirus diseasesspa
dc.subject.keywordCelecoxibspa
dc.subject.keywordCyclooxygenase (cox)-2 specific inhibitorsspa
dc.subject.keywordSymptomatic treatmentspa
dc.subject.keywordThroat pain on swallowingspa
dc.subject.keywordViral pharyngitisspa
dc.titleEfficacy of celecoxib in treating symptoms of viral pharyngitis: A double-blind, randomized study of celecoxib versus diclofenacspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
147323000203000212.pdf
Tamaño:
34.55 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos